Investing

Ironwood Pharmaceuticals : IRWD

IRWD

Stock Data

$5.23

$0.16 (2.97%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - SPECIALTY & GENERIC

Ironwood Pharmaceuticals Inc specializes in creating gastrointestinal (GI) treatments, offering relief for conditions like irritable bowel syndrome and chronic constipation through its flagship product, LINZESS. Beyond its core offerings, the company is exploring new therapies for visceral pain and rare diseases, including short bowel syndrome and primary biliary cholangitis. With strategic partnerships enhancing its reach, Ironwood stands out in the healthcare sector for its innovative approach to GI disorders and commitment to improving patient quality of life.

All Ironwood Pharmaceuticals Articles

18 Articles

Will Ashworth | Mar 17, 2025 at 3:01 PM EDT

Billionaire Healthcare Investor Alex Denner’s Hedge Fund Has 75% of Its Assets in These 3 Stocks 

If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t…

Lee Jackson | Sep 6, 2022 at 8:44 AM EDT

Tuesday’s Top Analyst Upgrades and Downgrades: Broadcom, Deere, FedEx, Lululemon, LyondellBasell, Nvidia, Starbucks and More

Tuesday's top analyst upgrades and downgrades included Broadcom, Ciena, Deere, FedEx, IMAX, Ironwood Pharmaceuticals, Lululemon Athletica, LyondellBasell Industries, Nvidia and…

Jon C. Ogg | Feb 25, 2019 at 8:50 AM EST

Top Analyst Upgrades and Downgrades: Allscripts, AmeriGas, CVS, IMAX, Kraft Heinz, Marathon Oil, Microsoft, Pfizer and Many More

The top analyst upgrades, downgrades and initiations seen for Monday included Allscripts Healthcare Solutions, AmeriGas Partners, CVS Health, IMAX, Kraft…

Jon C. Ogg | Nov 7, 2018 at 9:00 AM EST

Top Analyst Upgrades and Downgrades: AIG, Freeport-McMoRan, Frontier Communications, Noble Energy, Occidental, Spark Therapeutics, Target and More

The top analyst upgrades, downgrades and initiations seen on Wednesday included AIG, Freeport-McMoRan, Frontier Communications, Noble Energy, Occidental Petroleum, Spark…

Chris Lange | Jan 5, 2018 at 11:15 AM EST

Meet Merrill Lynch’s Top Biotech Picks for 2018

Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and…

Jon C. Ogg | Nov 27, 2017 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: AECOM, Ciena, Evoqua Water Tech, Funko, GlaxoSmithKline, Square and Many More

The top analyst upgrades, downgrades and other research calls from Monday include AECOM, Ciena, Evoqua Water Tech, Funko, GlaxoSmithKline and…

Chris Lange | Aug 21, 2017 at 11:38 AM EDT

Ironwood Pharma Muted Despite FDA Approval

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares remained relatively muted on Monday after the firm announced a key U.S. Food and…

Lee Jackson | May 19, 2017 at 8:25 AM EDT

JPMorgan’s Favorite Biotechs to Buy With Massive Upside Potential

After a couple of down years in which the shrill political rhetoric over drug prices kept a pall over the…

Jon C. Ogg | May 3, 2017 at 9:15 AM EDT

Top Analyst Upgrades and Downgrades: Anadarko, Apple, Charter Communications, FireEye, First Solar, Frontier Communications and More

The top analyst upgrades, downgrades and other research calls from Wednesday include Anadarko, Apple, Charter Communications, FireEye, First Solar and…

Lee Jackson | Apr 6, 2016 at 8:55 AM EDT

Top Analysts Upgrades and Downgrades: Alphabet, Apple, Duke Energy, Kellogg, NVIDIA, Wells Fargo and More

Wednesday's top analyst upgrades, downgrades and initiations include Alphabet, Apple, Duke Energy, Kellogg, NVIDIA and Wells Fargo.

Jon C. Ogg | Mar 21, 2016 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: AK Steel, Intel, Symantec, Tesla, US Steel, Valeant and More

The top analyst upgrades, downgrades and initiations seen on Monday, March 21, include AK Steel, Intel, Symantec, Tesla, US Steel…

Jon C. Ogg | Sep 4, 2014 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: Google, GoPro, Infinity Pharma, 3D Systems, LifeLock and More

These are the top analyst upgrades and downgrades covered by 24/7 Wall St. on Thursday, September 4, 2014.

Jon C. Ogg | Apr 23, 2014 at 10:50 AM EDT

Companies Betting on the Next 10 Blockbuster Drugs

24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in…

Trey Thoelcke | Apr 7, 2014 at 8:25 AM EDT

Credit Suisse Says Grit Your Teeth and Buy Biotech

In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016…

Lee Jackson | Sep 4, 2013 at 8:25 AM EDT

UBS Picks Large Cap Biotechnology Stocks to Outperform the Rest of 2013

ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive…